Introduction (Reference Points, Coordinate Systems and Volumes)
To achieve accurate radiation therapy, it must be possible to precisely relate the positions of tissues, organs or volumes in the patient to the positions and orientation of beams used for both imaging or therapy. This requires the use of three coordinate systems, one within the patient, one related to the imaging unit and one related to the treatment machine. The positions of organs, tissues and treatment-related volumes are related to anatomical reference points or alignment marks and the coordinate system within the patient. The position and orientation of the imaging and treatment machines are defined in coordinate systems related to these machines. The reference points serve to link the coordinate systems since they can be defined in both patient and machine coordinates. The coordinates of the "target" can then be defined in the external coordinate system during dose planning.
Reference Points
Alignment of the patient in a reproducible and stable position is a prerequisite for correct definition of volumes and set-up of beams. Adequate patient immobilization systems are the most effective means to accomplish this. Reference points, either internal or external or alignment points or lines are then used to establish the patient coordinate system and for reproducible alignment ofthe patient for imaging or treatment.
Internal Reference Points are anatomical landmarks (e.g., bony structures or gas-filled cavities) which may be used for localization of the Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) and for accurate set-up at the imaging unit, simulator and treatment unit. Often separate reference points must be used for different beams and if there is more than one GTV or CTV.
External Reference Points are palpable or visible points located on or near the surface ofthe body or on the surface of immobilization devices that fit closely to the exterior of the body (e.g., face masks, bite blocks and shells). As External Reference Points, one may also use skin markings or alignment tattoos that are reproducibly related to the body as a whole (e.g., to skeletal structures).
Coordinate Systems
Three types of coordinate systems are involved in the planning and execution of radiation treatments.
Coordinate System Related to the Patient. The reference coordinate system for the patient is based on either internal or external reference points. The coordinate system is defined with one of the reference points as origin and other reference points for orientation ofthe system and alignment ofthe patient.
Coordinate Systems Related to Imaging and Treatment Units. These coordinate systems are defined with respect to the gantry, collimators, radiation beam, light beams, laser-alignment beams and couch-top system.
For example, Fig. 2 Example of a suggested set of coordinate systems: Cp = The reference system related to the patient, in relation to an internal reference point. C, = The reference system related to the imaging unit used for collecting information (e.g., CT scanner). C R = The reference system related to the therapy unit for variations in patient and beam geometry, in relation to an external reference point. (Modified from ICRU Report 42 (ICRU, 1987) .)
Volumes
The process of determining the volumes for the treatment of a patient with malignant disease consists of sequentially specifying different tissues, organs, and volumes three-dimensionally.
These volumes are (Figs. 2.13, 2.14, and 2.16 ): Gross Tumor Volume (GTV), Clinical Target Volume (CTV),
Planning Target Volume (PTV), Treated Volume, Irradiated Volume, Organs at Risk (OR), and Planning Organ at Risk Volume (PRV). Each of these are discussed below. It should be noted that the GTV and the CTV represent volumes with known or suspected tumor involvement, and the OR represents normal tissues; the others are purely geometric concepts, which do not strictly correspond to tissue or organ borders.
Gross Tumor Volume (GTV)
The Gross Tumor Volume (GTV) is the gross demonstrable extent and location of the malignant growth.
The GTV consists of primary tumor ("GTV primary") and possibly metastatic lymphadenopathy ("GTV nodal") or other metastases ("GTV M"). The GTV almost always corresponds to those parts ofthe malignant growth where the tumor cell density is the highest. Hence, an adequate dose must be delivered to the whole GTV to achieve the aim of radical therapy.
It may not be possible to define a GTV after surgical intervention.
The shape, size, and location of a GTV may be determined by clinical examination (e.g., inspection, palpation, endoscopy) and/or various imaging techniques (e.g., x-ray, CT, digital radiography, ultrasonography, MRI, and radionuclide methods). The methods used to determine the GTV should meet the requirements for scoring the tumor according to the TNM (DICC, 1997) andAJCC (AJCC, 1997) systems. The definition of the GTV should then be in full agreement with the criteria used for the TNMclassification. An example is given in Fig. 2 
.2.
The GTV (primary tumor, metastatic lymphadenopathy, other metastases) may appear different in size and shape, sometimes significantly, depending on which examination technique is used for evaluation, e.g., palpation, mammography, x-ray, and macroscopic examination of the surgical specimen for breast tumors (example given in Fig. 2.3.) , CT, and MRI for some brain tumors. The radiation oncologist should indicate which method has been used for evaluation and for the definition of the GTV. However, even using the same techniques, inter-observer variation may be significant (Fig. 2.4.) .
A GTV may be confined to only part of an organ (e.g., a Tl breast cancer) or may involve a whole organ (e.g., in multiple metastases to the brain). The GTV mayor may not extend outside the normal borders of the organ tissue involved.
For reporting, the Gross Tumor Volume should be described in standard topographical or anatomical terms, e.g., "18 mm X 12 mm X 20 mm tumor in the Examination shows a 45 mm X 35 mm x 40 mm large partly ulcerated tumor in the left part of the floor of the mouth. The tumor extended into the tongue, deeply infiltrated the muscles, but did not reach the midline. No regional lymphadenopathy. Biopsy showed moderately well differentiated infiltrating squamous cell carcinoma.
Thus:
Clinical diagnosis: Oral carcinoma OCD-02 = C04.9) Tumor type and grade: Moderately well differentiated infiltrating squamous cell carcinoma, (SNOMED = 807032, TNM grade = G2).
Clinical tumor extent and stage: T4 NO MO = IVA. GTV: site = floor of the mouth left and mobile tongue left (anatomical code, ICRU 50, Table 1 .2 = C04.9-2 + C02.9-2).
(Courtesy of the Malmo University Hospital, Sweden) left lobe ofthe prostate adjacent to but not breaching the capsule." In many situations, a verbal description might be too cumbersome; therefore, for the purpose of data recording and analysis, a classification system is needed. Several systems are proposed for coding the anatomical description; some of them are mentioned in ICRD Report 50 (lCRD, 1993) . There are at least three reasons to describe and report the GTV in a complete and accurate way. Firstly, as indicated above, it is required for staging, e.g., according to the TNM system. Secondly, an adequate dose must be delivered to (at least) the whole GTV in order to obtain local tumor control in radical treatments (otherwise the probability oflocal control decreases). Thirdly, regression of the GTV during treatment may be used with care as predictive oftumor response. Depending on which examination method is used to est a blish the size of t h e Gross Tumor Volume, one may arrive a t different T/pT-categories (and even differ ent stages) in the TNM-classification. (Courtesy of the Malmo University Hospital, Sweden.) (CTV) The Clinical Target Volume (CTV) is a tissue vol ume that contains a demonstrable GTV and / or subclinical malignant disease that must be eliminated. This volume must be treated adequately in order to achieve the aim of radical therapy.
Clinical Target Volume
The Clinical Target Volume is, like the GTV, a purely clinical-anatomical concept and can be described as including structures with clinically suspected but unproved involvement, in addition to any known tumor (hence "subclinical disease").
Macroscopically, tumors may seem relatively well demarcated or may have no distinct borders (Fig. 2.5.) .
When microscopic examination of a cancer is performed, one often finds subclinical extensions around the GTV (Fig. 2.6. ). Furthermore, areas suspected of subclinical involvement, e.g., regional lymph nodes (NO), may be considered for therapy.
Thus, two types of subclinical disease (surrounding the GTV and at a distance, e.g., lymph nodes) can be envisaged, as illustrated in Fig. 2.7 . The prescription is then based on the assumption that, in some anatomically definable tissues/organs, there may be cancer cells at some probability level, even though they cannot be detected with present day techniques; these are subclinical. The estimate of probability is based on clinical experience from adequately documented treatments and follow-up. For prescription of treatment, these subclinical deposits (or their probability of existence) can be described in terms of risk for later detectable manifestations ifnot treated adequately at this subclinical stage.
In a particular patient, there may be more than et al., 1993.) one CTV for which different doses are prescribed. One situation is illustrated ( Fig. 2.7 .) by considering a primary tumor and its regional lymphatics separately (e.g., in breast saving procedures) where the primary tumor and its regional lymphatics are separated anatomically. In other situations, the aim is to treat two or more CTVs to different dose levels. One example of this is boost therapy, where often the high-dose volume (often containing the GTV) is located inside the low-dose volume.
Prescription of Treatment of Subclinical Extensions Adjacent toaGTV
Clinical experience indicates that outside the GTV there is generally subclinical involvement, i.e., individual malignant cells, small cell clusters, or micro-extensions that cannot be detected by the staging procedures. The GTV, together with this surrounding volume of local subclinical involvement, can be defined as a Clinical Target Volume (CTV) if the same dose is prescribed. This CTV will then usually be denoted Clinical Target Volume One (CTV D. If the GTV has been removed by radical surgery, but radiotherapy is considered necessary for the tissues that remain close to the site of the removed GTV, this volume is also usually designated as CTV I.
Prescription of Treatment of Subclinical Extensions at a Distance from a GTV
Additional volumes (CTVs) with presumed subclinical spread (e.g., regional lymph nodes) may also be considered for therapy. They are also defined as Clinical Target Volumes and may be designated CTV II, CTV III, etc.
For reporting, the Clinical Target Volume must be defined in plain anatomical terms and/or according to a corresponding code (see for example Table I .2. in ICRU Report 50) in conformity with the recommendations for the GTV Identification and description of the GTV(s) and CTV(s) is thus part of the treatment prescription.
It must be stressed that the prescriptions of the GTV(s) and CTV(s) are based on general oncological principles, and they are independent of any therapeutic approach. In particular, they are not specific to the field of radiation therapy. For instance, in surgery, a safety margin is taken around the Gross Tumor Volume according to clinical judgment, and this implies the same use of the Clinical Target Volume concept as in external beam radiation treatments. Also in brachytherapy, volumes to be treated must be defined, and thus the concept ofCTV is used. The definitions ofGTV(s) and CTV(s) constitute part of the basic prescription of the treatment; they are essential to the medical record. Their definition must precede the selection of the treatment modality and the subsequent treatment planning procedures.
Planning Target Volume (PTV)

Margins for Geometric Variations and Uncertainties
Once the CTV(s) has (have) been defined and external-beam radiation treatment adopted as the treatment modality, a suitable arrangement of beam(s) must be selected in order to achieve an acceptable dose distribution. Computation of dose distribution can currently be done only for a static representation; whereas, in fact, there are variations and uncertainties in the positions, sizes and shapes, and orientations of both the tissues, patient, and the beams in relation to the common coordinate system. This will be seen both during a single session (intrafractionally) and from one session to another (interfractionally). Errors can also be introduced between the imaging procedure and the treatment planning and between the treatment planning and first treatment session.
Dose distributions represent static situations and do not inherently reflect uncertainties in positioning ofthe organ/patient with respect to the beams. If this is not taken into account and if no margins are added, some of the tissues may, for part of the treatment, move in or out of the therapeutic beam; and this will result in over-or underdosage. Other parts of the tissues may move around in a dose gradient, and then it will be difficult to state the exact dose received by each part of the tissues . On the other hand, using margins that are very large will result in unnecessary morbidity. There is no ideal solution, and one must search for an acceptable compromise.
To avoid significant deviation from the prescribed dose in any part ofthe CTV(s), one must add margins to the CTV(s) for variations in tissue position, size, and shape, as well as for variations in patient position and beam position, both intrafractionally and interfractionally. This leads to the concept ofthe Planning Target Volume (PTV), (ICRU Report 50 [ICRU,1993] ).
It is difficult to quantify the different types of variations and uncertainties, as well as their interactions. One is thus forced to make assumptions and, in some cases, to combine the different variations and uncertainties accordingly. Recent developments, e.g. , in electronic portal imaging (Holmberg et al., 1994; Ekberg et al., 1998) and other techniques (Ross et al. , 1990; Schwartz et al., 1994) now allow for a better quantification of some of these parameters. Other technical improvements, such as respiratory gating of the beam output, may influence the width ofthe selected margins.
For the final treatment plan (definition of beam sizes, etc.), all the variations and uncertainties must be considered, and their overall effect should define a static volume (Planning Target Volume [PTV]). The need for the margins, included in the PTV, thus results from a number of geometrical variations and uncertainties in r elation to the reference point and coordinate system. They are listed in 10 Distance (cm) from the (pathologically estimated) reference tumor Fi g. 2.6. Example of the distribution of tumor foci at ditTerent dist:mces from the oorder of the Gross 'fumor Volume I~refer ... nce WmOrH). This graph show!! the remaining proportion of cases with tu mor foci at or be~'ond the specified distance from the reference tumor. The percentages given within the groups indicate the proportion of cases with tumor foci located at or beyond the point given on the abacisl>u (i.e., distance from reference tumor). A: No tumor foci outside the reference tumor. These cases constitute 41% of all cases. B: 'fumor foci within 2 em of the reference tumor. These cases constitute 17%ofa!l cases. The exact distance of these foci and their inv:ts;vl< or noninvasive character was not furthL'T specified. C: Noninvasive tumor foci extending farther than 2 cm [rom the reference tumor. These cases CQnstitute 28% of all cases. D: Invasive t umor foci extending farther than 2 em from the reference tumor. These cases constitute 14% of all cases. ul. , 1985 ul. , . [CANCER, 56, 1985 The definition of a margin can either account for a ll potential variations and uncertainties or include only a certain proportion (e.g .. 2 standard deviations). Other considerations may a lso be needed , e.g., if only normal breathing is included , but the effects of an occasional deep breath are disregarded (see Table 2 .2). Information on such decisions is useful.
Redrawn from Holland e/
The problem of margins to a llow for geometrical variations and uncertainties is currently the subject of much interest . General overviews of the problem, includ ing the application of risk philosophy and biometrical models can be found in reports by Michalski (1994) , Austin-Seymour et. al. (1995a , 1995b , Purdy et al. (1996) , and Aaltonen-Brahme et at. In order to determine margins, it is useful to think of the two types of uncertainties, internal and set-up margins .
2.4.1 .1. Intern a l Ma rgin (1M) a n d Inte rna l Target Volume (lTV). A margin must be added to tbe CTV to compensate for expected pbysiologic movements and variations in size, shape, and position of the CTV during therapy in relation to an Internal Reference Point and its corresponding Coordinate System. It is now denoted as the Interna l Margin (1M).
The Internal Margin , commonly asymmetric around the CTV, is intended to compensate for a ll --0
7. Schematic example of II CTV (demonijtrabJe tumor " striated area ) and a11>O for CTVs to care for suspected, subclinical extensions surrounding the Gross Tumor Volume (CT\' 1, here also including theG'IV) and to regional lymph nodes (CTV II , '" open a~a). The tumor l'elJ density is high in the GTV, but may be heterogeneous (e.g., due to necrosis). Close to the GTV (supposing that there is no natural lwatomlcal borner such as the parietal pleura in mediastinal lymphomas), one has to ex pect II zone with subclinical extensions. probablY with overall decreasing tumor cell density with distance. The true variation in cell density in this zone (safety margin) is difficult to assess and probably varies with tumour type and location. For the clinical example shown here, in the regional lymphatics and lymph nodes, no Gross 'TUmor could be demol1strllted (NO ); but, based on clinical expericnce. it was assumed thllt thcre could be subclinical extensioZlli to the lymph nodes, but not to the connecting lymph vessels.
movements and all variations in site, size, and shape of the organs and tissues contained in or adjacent to the CTV They may result , e.g. , from respiration, different fillings of the bladder, different fillings of the rectum , swallowing, heart beat, movements of the boweL These internal variations are thus basically physi· ological ones, and they result in changes in site, size, and sha pe of the CTV. They cannot be easily controlled. They do not depend on external uncertainties in beam geometry, but could depend on patient day-to-day set-up.
The term Internal Target Volume (lTV) has been proposed (Landberg et al., 1996; and Aaltonen-Brahme el-al., 1997) as representing the volume encompassing the CTV and the Internal Margin. The lTV is related to the patient coordinate system.
2.4_1.2 Se t-up Margin (SM). To account specifically for uncertainties (inaccuracies and lack of reproducibility) in patient positioning and alignment of the therapeutic beams during treatment planning and through all treatment sessions, a Set-up Margin (SM) for each beam is needed . The Set-up Margin is referenced in the external coordinate system. The uncertainties to he compensated for may vary with different anatomical directions, and thus the size of such margins depends on the selection of beam geometries. The uncertainties de~ pend on different types of factors, such as: variations in patient positioning, mechanical uncertainties of the equipment (e.g., sagging of gantry, collimators, and couch), dosimetric uncertainties, transfer set-up errors from CT and simulator to the treatment unit, human factors. These may vary from center to center and, within a given center, from machine to machine. The use of patient immobilization devices, the application of quality assurance programs, and h uman factors such as skill and experience of the radiographers! radiotherapists are important and must be taken into account. The use of different record and verifica~ tion systems (in real time or not) may also be important and may significantly alter the size of the needed set·up margins. Fig. 2 . 14. illustrates schematically the different margins and volumes, as well as their relations.
Note t hat in some cases, the Internal Margin approaches a very low value, (e.g., with brain tumors), and in other cases the Set-u p Margin may be very small (e.g., with on-line correction for the different set·up errors and variations). The Planning Target Volume (PTV) is a geometrical concept used for treatment planning, and it is defined to select appropriate beam sizes and beam arrangements, to ensure that the prescribed dose is actually delivered to the CTV.1 . Del~neation of the PTV is a matter of compromise, Implymg the judgment, and thus the responsibility, o~ the radiation oncologist and the radiation physi-CIst together.
The border of the PTV must be clearly identified on charts for treatment planning. For the purpose of dose specification for reporting and for evaluation of a Conformity Index (see below), the surface that defines the PTV must be closed, even if this may not be necessary for the proper selection of beam parameters (see e.g., Beam's Eye View, BEV, Fig. 2.15 ., and AP-PA treatments, Fig. 2.17.a.1) . 1 Note that the definition of the Planning Target Volume (PTV) as introduced in ICRU Report 50 (ICRU, 1993) , and used in this Report, is identical to the previous definition of "Target Volume" in Report 29 (ICRU, 1978) . As will be discussed below, the different variations and uncertainties may be either of type A or B (" d " " t .,,) h ran om or sys ematlc ; t ey may be independent from each other or related in different ways. Their size may differ for different parts of a CTV (e.g., base versus apex of the bladder and prostate), and at different times (e.g., with the respiratory cycle). The situation for a single patient may be quite different from that for a patient population.
Depending on the clinical situation (e.g., patient condition and site of the CTV) and the chosen technique, the PTV could be very similar to the CTV (e.g., small skin tumors, pituitary tumors) or, by contrast, much larger (e.g., lung tumors). Since the PTV is a purely geometric concept that must be related to the basic anatomical description, it may extend beyond normal anatomical borders (e.g., include parts of clinically unaffected bony structures).
In a typical example of tangential irradiation of the breast, respiratory movements cause the PTV to move and extend outside the average position of the body contour (Fig. 2.13.) . The situation should be handled according to general rules when appropriate beam sizes are selected to compensate for these geometrical uncertainties. However, in these cases, there will be a problem when the absorbed dose distribution for the PTV is calculated and displayed, since this cannot be done in a meaningful way outside the body contour, when shown in a single, "average," static representation. As an approximation, one can perform the dose computation assuming the normal tissues to be in the extreme position (moved towards the surface, see Fig. 2 .13., dashed line) so that the absorbed dose distribution to the CTV is similar to the one that would be found ifthere were no geometrical uncertainties and then calculate and display the dose distribution to the PTV. In any case, it is recommended that a description be given of the method that was used.
One difficulty in choosing a PTV results from the presence of radiosensitive normal tissue(s) (Organs at Risk, see definition below). If a compromise between an adequate selection of a PTV and the risk of complications is unsatisfactory for a provisional beam arrangement, then alternative beam arrangements must be considered as part of an optimization procedure. If the PTV and the PRY overlap (see section 2.7.2.), this must be considered when prescribing dose and fractionation. In some cases, it may be necessary to change the prescription (for volumes and/or dose levels) and then accept a changed probability of benefit. When, for radical treatments, the probability of local control diminishes, then the aim of therapy may shift from radical to palliative.
Adding or Combining the Margins
When choosing a PTV, the different types of margins identified above must be added or combined. Different scenarios are depicted in Fig. 2.16 .
In choosing margins, the risk of missing part ofthe CTV must be balanced against the risk of complications due to making the PTV too large. For instance, if margins are added linearly, the resulting PTV may often be too large, with a consequent risk of exceeding patient tolerance.
Since margins are introduced to compensate for both random and systematic uncertainties, a quadratic combination approach similar to that recommended by the Bureau International des Poids et Mesures (BIPM, 1981) is often employed. This may provide a means to combine random and systematic, as well as correlated and uncorrelated uncertainties. In many instances, this process provides realistic and acceptable results (Mijnheer et al., 1987) . Unfortunately, this ideal approach can be applied strictly only in situations where one can identify the causes or errors and quantify the uncertainties (e.g., by standard deviation). Currently, this is not generally possible except for a few situations (e.g., some conformal therapy protocols).
In practice, at present, the PTV must be delineated by the radiation oncology team based on experience and judgment drawn from observation and evaluation of the risk of failure and complications. In any case, the method used to select margins and their widths must be clearly reported.
NOTE: THE PENUMBRA
The penumbra of the beam(s) is not considered when delineating the PTV. However, when selecting the beam sizes, the width of the penumbra has to be taken into account and the beam size adjusted (enlarged) accordingly.
Treated Volume
General Aspects
Due to limitations of irradiation techniques, the volume receiving the prescribed dose does not generally match the PTV; it may be larger (sometimes much larger) and in general more simply shaped. This leads to the concept of Treated Volume.
The Treated Volume is the tissue volume that (according to the approved treatment plan) is planned to receive at least a dose selected and specified by the radiation oncology team as being appropriate to achieve the purpose of the treatment, e.g., tumor eradication or palliation, within the bounds of acceptable complications.
The Treated Volume is the volume enclosed by the isodose surface corresponding to that dose level. The relative value of the isodose that was selected to define the Treated Volume in relation to the dose at the ICRU Reference point should be stated when reporting. Alternatively, the value of the dose level that was selected to define the Treated Volume can be expressed in absolute values. For example, if the prescribed dose at the ICRU Reference Point is 60 Gy and if a dose variation between +7% and -5% is accepted in the PTV, the Treated Volume is enclosed by the 57 Gy (= 95% ofthe 60 Gy) isodose surface.
The delineation of the Treated Volume is completed when the treatment planning procedure is completed and the beam arrangement, as well as all other irradiation parameters, have been verified. It is the aim of Quality Assurance Procedures to ensure that actual Treated Volume corresponds to the planned Treated Volume.
It is important to identify the Treated Volume and its shape, size, and position in relation to the PTV for several reasons. One is to evaluate and interpret causes for local recurrences ("in-field" versus "marginal"). Another is to evaluate and interpret complications in normal tissues (encountered outside the PTV but within the Treated Volume).
Conformity Index (CI)
A Conformity Index (CI) can be employed when the PTV is fully enclosed by the Treated Volume, then being the quotient of the Treated Volume and the volume of the PTV. A similar "Radiation Conformity Index (RCI)"was proposed by Knoos et al. (1998) .
The CI can be used as part of the optimization procedure. It must be stressed that when defining the CI, it is implied that the Treated Volume totally encompasses the PTV.
Irradiated Volume
The Irradiated Volume is the tissue volume that receives a dose that is considered significant in relation to normal tissue tolerance.
If the Irradiated Volume is reported, the significant dose must be expressed either in absolute values (in Gy) or relative to the specified dose to the PTV. The Irradiated Volume depends on the treatment technique used.
Note that the size of the Irradiated Volume relative to the Treated Volume may increase as the number of beam directions increases (Fig. 2.17 and Table 2 .3.). This implies a compromise, and it is the responsibility of the radiation oncology team to select what is judged to be the optimal treatment. In "conformal therapy" using beam shaping, e.g., by MLC (Multi Leaf Collimator), or customized blockings, both Treated Volume and Irradiated Volume can be reduced.
Organs at Risk (OR)
Definition of Organs at Risk
Organs at Risk ("critical normal structures'') (see also section 3.5.) are normal tissues (e.g., spinal cord) whose radiation sensitivity may significantly influence treatment planning and / or prescribed dose Note: An example of treatment of a prostatic adenocarcinoma, using 2, 3, and 4 intersecting beams and arc therapy (open beams i.e., square or rectangular), and 3 and 4 intersecting beams with multileaf collimator (conformal therapy). The dose distributions are displayed in Fig. 2.17 . The 100% isodose is taken at the ICRU Reference Point (intersection of beam axes). The Treated Volume is enclosed in the 95% isodose surface, and the Irradiated Volume by the 50% isodose surface. When the number of beams is increased, the Conformity Index (CIg5 ), (i.e., the ratio between the Treated Volume and the PTV) decreases (comes closer to unity). This is not the case with the Irradiated Volume. The use of the multileaf collimator definitely improves the situation. (From N. Gupta, Ph.D., The Ohio State University). ......... -...... ... ...... ... ......... ... ... ... ...... 'T ... ... ...... ... ...... ... ... -, -... ... -... ... ... _ ...... ... ... --... ... _ ... ... ... --............ -. . 
Notes:
(1 ) For explanation, see Sections 2.1-2.7.
(2) The Internal Margin may be asymmetrical.
(3) Like the Internal Margin, the Set-up Margin may also be asymmetrical.
(4) To delineate the PTV, the 1M and SM are not added linearly (s ince this could result in an excessively large PTV), but are combined essentially subjectively (for explanation, see text ). The PTV is thus smaller than if one wou ld simply have added the 1M and 8 M linearly. (5) For Organs at Risk (ORl, margins are added in the same way as for the PTV. (6) The PTV and PRY mayor may not overlap.
Presently, our knowledge about the sensitivity of normal tissues is derived mainly from clinical observations. However, different approaches have been proposed for the modeling of normal tissue complication probability (NTCP): the empirical model introduced by Wolbarst et all (1982) ; and also described by Lyman (1985) , and the functional models based on the FSU (Functional Sub Unit) concept (Withers et all [1988] , Willman et all [1992] , and Olsen et all [1994] ).
The FSU-concept suggests that, for the purpose of evaluation of the volume-fractionation-response, the tissues of an Organ at Risk can be considered to be functionally organized as either "serial," "parallel," or "serial-parallel" structures ( Fig. 2.18.) . For example, the spinal cord has a high "relative seriality," implying that a dose above tolerance limit to even a small volume of this Organ at Risk may be deleterious; whereas, the lung usually has a low "relative seriality," meaning that the most important parameter is the relative size of the volume that is irradiated above tolerance level.
Late effects from mantle treatment for Hodgkin's disease may serve as an example (Gustavsson et al., -..... .. ..... -. . ........ --\\>l • • • • · · · · · ·~--. . . 1990, 1992) . At similar doses, the late effects from the (partial) irradiation of the lungs (a parallel tissue) were much less serious than those from the heart (a combined serial [coronary arteries] and parallel [myocardium] tissue).
For the moment, the model has not been tested enough to allow for firm recommendations, but indeed it highlights an important problem. It may be useful to state whether the Organ at Risk is considered to be arranged mainly serially, mainly in parallel, or mainly in a mixed serial-parallel fashion.
Planning Organ at Risk Volume (PRV)
As is the case with the Planning Target Volume, any movements of the Organ(s) at Risk during treatment, as well as uncertainties in the set-up during the whole treatment course, must be considered.
An integrated margin must be added to the OR to compensate for these variations and uncertainties, using the same principles as for the PTv. In particular, Internal and Set-up margins can be identified.
This leads, in analogy with the PTV, to the concept of Planning Organ at Risk Volume (PRV).
For reporting, it is recommended that, as for the PTV, the PRV be described by including the size of the combined margins of the Organ at Risk in different directions.
Note that a PTV and a PRV may overlap.
Recommendations for Recording and Reporting Volumes
When reporting a radiation treatment, some important oncological information must be given first, e.g., the description (plural, when relevant) ofthe • Gross Tumor Volume (GTV),
• Clinical Target Volume (CTV). Then, the information concerning the treatment itself must be given, in particular:
• Planning Target Volume (PTV), Treated Volume, Irradiated Volume, Planning Organ at Risk Volume (PRV). The description ofthe Planning Target Volume is a key point in the description of the treatment. Delineation of the Planning Target Volume is always a compromise, implying the judgment, experience, and thus the responsibility of the radiation oncology team. The different margins that were added or combined as well as the Organs at Risk that were considered when defining the PTV should be clearly described so that the aim of the treatment and the doses that are reported can be understood unambiguously.
Furthermore, as a general recommendation, additional relevant information should be reported.
Graphics
It is common practice to mark the position of anatomical structures with different colors to promote the proper interpretation ofthe decisions made. A common example is to depict "the tumor" in red. In treatment planning, different colors will be used for anatomic structures, "regions of interest," beam geometry, and distribution of absorbed dose. The colors must be easily interpreted.
For the moment, there is no general agreement on the choice of different colors or shades for these purposes.
In this report the following convention is recommended and has been used: 
CTV
The arrow illustrates the influence of the organs at risk on delineation of the PTV (thick,fuliline) . In case further ORs are identified, to avoid confusion, additional colors can be selected, e.g., yellow (or brown) (dark color indicating the OR, and corresponding light color indicating the PRY). Where the figures in this report have been prepared specifically for this document, the recommended color code has been used, but where the figures are taken from other sources, the original author's scheme is replicated.
Gross Tumor Volume (GTV)
The volumes should be presented as color surfaces (Fig. 2.13.) and not just their contours.
It is important that new conventions such as these should be introduced in a department only if they can be expected to promote safety and when there is no risk of increased error or confusion.
Probability of Benefit and Risk of Complications
A safety margin around the GTV is generally irradiated to treat subclinical disease. Also regional lymph node areas are often irradiated for the same reason. This leads to the concept of the CTV (see section 2.3.). An additional safety margin is added to take into account the movements and the variations in shape and size ofthe CTV, as well as the variation and uncertainties in patient-beam positioning. This leads to the concept of the PTV (see section 2.4.).
The concept of a safety margin can also be applied to the OR, since, because of the movements of the organs in the body and the uncertainties in positioning of the beams in relation to the patient, there is a risk that the OR will receive an excessive dose. Ideally, one would prefer to irradiate only the tissues containing malignant cells, i.e., the GTV and the normal tissues actually involved by subclinical disease. In practice, one takes the risk of irradiating non-invaded tissues ifthe probability of involvement is high enough.
The probability of subclinical involvement around the GTV and in the regional lymph nodes can only be learned from clinical experience. It is then a matter of clinical judgement whether treatment of these tissues is justified. Other factors must be taken into consideration when making such a decision: the efficacy of irradiation of subclinical disease, or alternative methods of treatment (surgery or chemotherapy). One also must consider morbidity. In addition, one must avoid overtreating patients who will fail either locally or at a distance, or patients already cured by successful treatment of the GTV. Future diagnostic (imaging) methods can be expected to improve detection of (previously) subclinical disease, which can then become part of the GTV. However, the problem will not be eliminated totally; only the probability levels will be modified.
During the treatment planning procedure, additional margins must be added to the CTV in order to avoid underdosage of part of the CTV. Similarly, margins must be added around the OR in order to avoid overdosage of part of the OR. These two types of volumes and margins may overlap, and the best possible compromise must be found; it depends on the experience, judgement, and skill of the radio-A margin is added around the Gross Tumor Volume (GTV) to take into account potential "subclinical" invasion. The GTV and this margin define the Clinical Target Volume (CTV).
In external beam therapy, to ensure that all parts of the CTV receive the prescribed dose, additional safety margins for geometric variations and uncertainties must be considered.
An Internal Margin (1M) is added for the variations in position and/or shape and size of the CTV. This defines the Internal Target Volume. ... In any case, the presence of ORs always implies compromises, and it is necessary to apply the risk philosophy. When increasing or decreasing the width of the safety margins, the risk of missing part of the cancer cell population must be balanced by the risk Fig. 2.18 . Schematic examples of tissue organization structures in the parallel-serial model. (a) a serial string of subunits (e.g., the spinal cord), (b) a parallel string of subunits (e.g .• the lungs), (c) a serial-parallel string of subunits (e.g .• the heart), (d) a combination of parallel and serial structures (e.g., a nephron). (Modified from Withers et aI., (1988) and Kallman et al., (1992).) of increasing the number and/or severity of the complications. Further clinical quantitative information about the cost/benefit ratio will help to make the decisions more objective.
These situations are illustrated in Fig. 2 .16. A reasonable balance will have to be found for each individual patient.
